Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (219)	1/15/2002 2:38:33 AM
From: nigel bates	Read Replies (1) \| Respond to of 625

Another announcement I missed while Air France were losing my luggage... MELBOURN, England, Jan. 8 /PRNewswire/ -- Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT) and Immunex Corporation (Nasdaq: IMNX - news) announce today that Immunex has exercised an exclusive license option in respect of development and potential commercialization of human monoclonal antibodies. The exercise of the option, one of eight granted by CAT to Immunex under an agreement signed in December 2000, grants Immunex the exclusive right to develop human monoclonal antibodies specific for an undisclosed disease target. Accordingly, CAT has received a license fee and will potentially receive milestone and royalty payments on future antibody-based products developed and commercialized by Immunex...